ECHA reports on the progress made in 2021 in dossier and substance evaluation in line with Article 54 of REACH. 

Progress in compliance checks 

In 2021, ECHA continued its work on screening structurally similar substances in groups: 574 substances registered above 100 tonnes per year were screened. Out of these, ECHA selected 152 substances representing 38 groups for compliance check.   

Important hazard data has been requested to clarify concerns related to human health and environmental hazards, including those affecting reproduction and causing genetic mutations.
The Agency continued in 2021 checking compliance of those dossiers where registrants opted out from the joint submission and instead submitted their information separately. Checking these dossiers contributes to ensuring level playing field and supports the functioning of the internal market. The Agency checked compliance for 12 dossiers covering 10 substances submitted by companies opting out from joint submissions. Consequently, 11 draft decisions were sent for 9 substances. 

In 2021, ECHA carried out 300 full compliance checks covering 288 unique substances. The full checks focused on addressing relevant higher-tier hazard endpoints for substances or groups of substances of potential concern mainly in the higher tonnage bands. In addition, ECHA conducted 71 targeted compliance checks, which in total resulted in 371 checks covering over 2100 registration dossiers, and addressing 341 unique substances.

Outputs of dossier assessments in 2021 

Concluded assessments: 
ECHA performed 300 full compliance checks (CCHs) and 227 testing proposal examinations (TPEs), covering 489 unique substances. ECHA issued 467 draft decisions: 280 on the abovementioned compliance checks and  187 on testing proposal examinations. The selection of registrations for compliance check was mainly based on (groups of) substances raising potential hazard- or exposure-based concerns.